À propos de ce podcast
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
270 épisodes · Science
BioSpace
À propos de ce podcast
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
Épisodes récents
- AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll30 sept. · 20 min
- How radioligand therapy is rewriting cancer care24 sept. · 16 min
- Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz23 sept. · 21 min
- When vision fades: Rethinking wet AMD and the durability gap17 sept. · 22 min
- FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival16 sept. · 22 min
- The supply chain fault lines of modern pharma10 sept. · 36 min
- Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease9 sept. · 20 min
- Breaking borders: Building biotech scale in Benelux3 sept. · 19 min
- Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals2 sept. · 20 min
- Fragile X at a turning point: Breaking through the clinical bottleneck27 août · 19 min
podlinkr.com/fr/biospace
Pour une affiche ou une diapo.